Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Galectin Therapeutics Inc. (GALT)
USD4.88
-0.46 (-8.55%)
US NASDAQ Healthcare Biotechnology
Address
4960 Peachtree Industrial Boulevard 30071
Norcross, GA, US
Norcross, GA, US
CEO
Joel Lewis
Website
galectintherapeutics.com
IPO
2002-09-04
CIK 1133416 ISIN US3632252025
Description
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.88
-0.46 (-8.55%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
578.4K
Beta
0.49
Float Shares
46.86M
Free Float %
71.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.66% | +3.83% | -11.43% | -20.80% | -63.83% | -47.84% | +63.16% | +29.94% | -50.46% | +47.62% | -81.92% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (11 ratings, all time)
Buy
Price Targets & DCF
Current price
4.88
Low
11.00
+125.3%
Consensus
11.00
+125.3%
Median
11.00
+125.3%
High
11.00
+125.3%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
11.00
+125.3%
|
| All Time | 1 |
11.00
+125.3%
|
Quality scores
Altman Z-Score
-41.78
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+36.8% ★ Q1'26: +48.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +188.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2.6% ★ Q1'26: +4.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-5.70× Q1'26: -8.35× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 64.73M (-100.0%)
|
—
est: 208.00M (-100.0%)
|
—
est: 36.32M (-100.0%)
|
179.69M
179.69M – 179.69M
+394.7% YoY
|
385.24M
385.24M – 385.24M
+114.4% YoY
|
572.22M
572.22M – 572.22M
+48.5% YoY
|
23.10M
23.10M – 23.10M
-96.0% YoY
|
| EBITDA |
-38.24M
|
-41.47M
|
-23.45M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-38.27M
|
-41.51M
|
-23.51M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-41.07M
est: -29.91M (-37.3%)
|
-47.05M
est: -46.65M (-0.9%)
|
-30.84M
est: -31.31M (+1.5%)
|
-23.64M
-23.64M – -23.64M
+24.5% YoY
|
-21.09M
-21.09M – -21.09M
+10.8% YoY
|
-67.74M
-67.74M – -67.74M
-221.2% YoY
|
-58.15M
-58.15M – -58.15M
+14.2% YoY
|
| SGA |
5.94M
|
5.83M
|
5.80M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.74
est: -0.48 (-54.2%)
|
-0.76
est: -0.73 (-4.1%)
|
-0.48
est: -0.49 (+2.0%)
|
-0.37
-0.37 – -0.37
+24.5% YoY
|
-0.33
-0.33 – -0.33
+10.8% YoY
|
-1.06
-1.06 – -1.06
-221.2% YoY
|
-0.91
-0.91 – -0.91
+14.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
44
Total invested
15.28M
Insider transactions (90d)
0
Beneficial owners (>5%)
15
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 10X Capital Management, LLC | 50.86M | 44.60% | 50.86M | — | 50.86M | 11.00 | IA, HC, CO | State of Florida, United States | 2011-08-04 | ↗ |
| 2 | 10X Fund, L.P. | 50.86M | 44.60% | 50.86M | — | 50.86M | 10.00 | IV, PN | State of Delaware, United States | 2011-08-04 | ↗ |
| 3 | James C. Czirr | 47.80M | 51.10% | 6.16M | 41.64M | 6.16M | 11.00 | HC, IN | United States | 2010-03-29 | ↗ |
| 4 | C. Czirr | 13.89M | 30.10% | 1.56M | 12.33M | 1.56M | 12.33M | IN | USA | 2019-04-01 | ↗ |
| 5 | Capital Management, LLC | 12.33M | 26.80% | 12.33M | — | 12.33M | — | HC | of Florida, United States | 2019-04-01 | ↗ |
| 6 | Fund, L.P. | 11.86M | 23.30% | 11.86M | — | 11.86M | — | PN | of Delaware, United States | 2019-04-01 | ↗ |
| 7 | ( | 4.88M | 11.00% | — | — | — | — | IN | United States | 2003-02-07 | ↗ |
| 8 | Czirr | 4.70M | 19.50% | 19.4K | 19.4K | 19.4K | 19.4K | IN | States | 2004-08-24 | ↗ |
| 9 | David Platt | 4.55M | 18.90% | — | — | — | — | IN | United States | 2004-02-10 | ↗ |
| 10 | Platt | 4.54M | 16.60% | 10.9K | 10.9K | 10.9K | 10.9K | IN | States | 2005-02-10 | ↗ |
| 11 | Empery Asset Management, LP | 1.19M | 5.53% | — | — | — | — | PN | Delaware | 2015-11-24 | ↗ |
| 12 | Martin D. Hoe | 1.19M | 4.99% | — | 1.19M | — | — | IN | Delaware | 2016-01-19 | ↗ |
| 13 | Ryan M. Lane | 1.19M | 4.99% | — | 1.19M | — | — | IN | United States | 2016-01-19 | ↗ |
| 14 | CVI Investments, Inc. | 1.18M | 4.10% | — | 1.18M | — | 1.18M | CO | Cayman Islands | 2016-02-12 | ↗ |
| 15 | Heights Capital Management, Inc. | 1.18M | 4.10% | — | 1.18M | — | 1.18M | CO | Delaware | 2016-02-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
44
-58 vs prev Q
New positions
8
Closed positions
62
Increased
22
Reduced
9
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 48.0K +48.0K (+100.0%) | 199.68M +199.7M (+100.0%) | 0.07% +0.075 pp | 0.00% +0.002 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 2 | VANGUARD GROUP INC | 2.29M +40.9K (+1.8%) | 9.52M +1.5K (+0.0%) | 3.56% +0.022 pp | 0.00% +0.000 pp | USD4.92 -15.4% | 52 qtrs — |
| 3 | ADVISOR GROUP HOLDINGS, INC. | 1.09M -134.1K (-11.0%) | 4.54M -704.3K (-13.4%) | 1.70% -0.232 pp | 0.01% -0.001 pp | USD2.00 +108.0% | 24 qtrs — |
| 4 | BLACKROCK, INC. | 796.6K -1.1K (-0.1%) | 3.31M -64.4K (-1.9%) | 1.24% -0.017 pp | 0.00% +0.000 pp | USD2.71 +53.5% | 6 qtrs — |
| 5 | MARSHALL WACE, LLP | 602.1K +47.9K (+8.6%) | 2.50M +154.8K (+6.6%) | 0.94% +0.064 pp | 0.00% 0.000 pp | USD4.13 +0.7% | 3 qtrs — |
| 6 | WEALTHSPIRE ADVISORS, LLC | 602.0K +122.5K (+25.5%) | 2.50M +473.4K (+23.3%) | 0.94% +0.182 pp | 0.02% +0.009 pp | USD2.64 +57.6% | 26 qtrs — |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 598.1K -35.0K (-5.5%) | 2.49M -193.1K (-7.2%) | 0.93% -0.066 pp | 0.00% +0.000 pp | USD3.34 +24.6% | 52 qtrs — |
| 8 | COMMONWEALTH EQUITY SERVICES, LLC | 334.1K +39.2K (+13.3%) | 1.39M +140.8K (+11.3%) | 0.52% +0.056 pp | 0.00% +0.000 pp | USD2.19 +90.0% | 8 qtrs — |
| 9 | LPL FINANCIAL LLC | 325.3K -35.0K (-9.7%) | 1.35M -172.7K (-11.3%) | 0.51% -0.061 pp | 0.00% 0.000 pp | USD2.02 +105.9% | 32 qtrs — |
| 10 | GOLDMAN SACHS GROUP INC | 307.2K +285.2K (+1,295.6%) | 1.28M +1.2M (+1,270.9%) | 0.48% +0.444 pp | 0.00% +0.000 pp | USD4.01 +3.7% | 7 qtrs — |
| 11 | MORGAN STANLEY | 279.3K +51.0K (+22.3%) | 1.16M +194.8K (+20.1%) | 0.44% +0.075 pp | 0.00% +0.000 pp | USD2.64 +57.6% | 50 qtrs — |
| 12 | GENEOS WEALTH MANAGEMENT INC. | 243.3K -116.8K (-32.4%) | 1.01M -514.9K (-33.7%) | 0.38% -0.189 pp | 0.02% -0.014 pp | USD2.23 +86.5% | 40 qtrs — |
| 13 | STATE STREET CORP | 242.2K +11.9K (+5.2%) | 1.01M +32.2K (+3.3%) | 0.38% +0.014 pp | 0.00% +0.000 pp | USD3.19 +30.4% | 47 qtrs — |
| 14 | MILLENNIUM MANAGEMENT LLC | 235.5K +125.1K (+113.3%) | 979.7K +512.1K (+109.5%) | 0.37% +0.193 pp | 0.00% +0.000 pp | USD3.20 +30.0% | 19 qtrs — |
| 15 | VIVALDI CAPITAL MANAGEMENT LP | 204.1K -51.7K (-20.2%) | 848.9K -234.2K (-21.6%) | 0.32% -0.085 pp | 0.12% -0.038 pp | USD2.76 +50.7% | 27 qtrs — |
| 16 | JANE STREET GROUP, LLC | 199.3K +184.7K (+1,258.3%) | 829.3K +767.1K (+1,234.2%) | 0.31% +0.287 pp | 0.00% +0.000 pp | USD4.01 +3.7% | 3 qtrs — |
| 17 | RETIREMENT GUYS FORMULA LLC | 184.6K +18.6K (+11.2%) | 767.8K +64.8K (+9.2%) | 0.29% +0.026 pp | 0.35% +0.103 pp | USD2.06 +101.9% | 10 qtrs — |
| 18 | SOVRAN ADVISORS, LLC | 225.9K +68.5K (+43.5%) | 711.5K -86.5K (-10.8%) | 0.35% +0.104 pp | 0.06% -0.010 pp | USD2.16 +92.6% | 5 qtrs — |
| 19 | 683 CAPITAL MANAGEMENT, LLC | 162.5K +162.5K (+100.0%) | 675.9K +675.9K (+100.0%) | 0.25% +0.253 pp | 0.03% +0.029 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 20 | WELLINGTON MANAGEMENT GROUP LLP | 142.2K +142.2K (+100.0%) | 591.6K +591.6K (+100.0%) | 0.22% +0.222 pp | 0.00% +0.000 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 21 | NORTHERN TRUST CORP | 130.4K +9.4K (+7.8%) | 542.7K +30.0K (+5.8%) | 0.20% +0.012 pp | 0.00% +0.000 pp | USD3.00 +38.7% | 50 qtrs — |
| 22 | CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | 126.0K +4.8K (+4.0%) | 524.0K +11.0K (+2.1%) | 0.20% +0.005 pp | 0.00% +0.000 pp | USD3.05 +36.4% | 28 qtrs — |
| 23 | BARCLAYS PLC | 106.4K +77.8K (+272.2%) | 442.6K +364.0K (+463.0%) | 0.17% +0.121 pp | 0.00% +0.000 pp | USD4.18 -0.5% | 7 qtrs — |
| 24 | FORTIS CAPITAL ADVISORS, LLC | 106.1K +106.1K (+100.0%) | 441.5K +441.5K (+100.0%) | 0.17% +0.165 pp | 0.07% +0.065 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 25 | BELPOINTE ASSET MANAGEMENT LLC | 106.1K +106.1K (+100.0%) | 441.5K +441.5K (+100.0%) | 0.17% +0.165 pp | 0.02% +0.016 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 26 | GSA CAPITAL PARTNERS LLP | 102.0K +14.9K (+17.1%) | 424.0K +55.0K (+14.9%) | 0.16% +0.022 pp | 0.04% +0.006 pp | USD4.23 -1.7% | 5 qtrs — |
| 27 | TRAYNOR CAPITAL MANAGEMENT, INC. | 101.6K +2.5K (+2.5%) | 422.7K +3.0K (+0.7%) | 0.16% +0.002 pp | 0.02% -0.001 pp | USD1.85 +124.9% | 10 qtrs — |
| 28 | HIGHTOWER ADVISORS, LLC | 88.4K +— (+0.0%) | 367.6K -6.6K (-1.8%) | 0.14% -0.002 pp | 0.00% +0.000 pp | USD1.58 +163.3% | 5 qtrs — |
| 29 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 82.5K +82.5K (+100.0%) | 343.1K +343.1K (+100.0%) | 0.13% +0.129 pp | 0.00% +0.003 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 30 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 79.1K +10.1K (+14.6%) | 329.1K +36.5K (+12.5%) | 0.12% +0.014 pp | 0.00% +0.000 pp | USD2.45 +69.8% | 6 qtrs — |
| 31 | HUDSON BAY CAPITAL MANAGEMENT LP | 78.1K +63.3K (+427.1%) | 325.1K +262.3K (+417.7%) | 0.12% +0.098 pp | 0.00% +0.001 pp | USD4.18 -0.5% | 2 qtrs — |
| 32 | QUBE RESEARCH & TECHNOLOGIES LTD | 74.6K +13.8K (+22.6%) | 310.5K +52.7K (+20.5%) | 0.12% +0.020 pp | 0.00% +0.000 pp | USD3.61 +15.2% | 5 qtrs — |
| 33 | TRUIST FINANCIAL CORP | 68.0K +— (+0.0%) | 282.9K -5.1K (-1.8%) | 0.11% -0.001 pp | 0.00% +0.000 pp | USD2.11 +97.2% | 3 qtrs — |
| 34 | OMERS ADMINISTRATION CORP | 63.2K +63.2K (+100.0%) | 262.9K +262.9K (+100.0%) | 0.10% +0.098 pp | 0.00% +0.002 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 35 | VIRTU FINANCIAL LLC | 53.6K +14.6K (+37.4%) | 223.0K +58.0K (+35.2%) | 0.08% +0.022 pp | 0.01% -0.001 pp | USD4.22 -1.4% | 2 qtrs — |
| 36 | XTX TOPCO LTD | 51.9K +51.9K (+100.0%) | 216.1K +216.1K (+100.0%) | 0.08% +0.081 pp | 0.01% +0.006 pp | USD4.16 +0.0% | 5 qtrs — |
| 37 | HORIZON KINETICS ASSET MANAGEMENT LLC | 51.5K -2.3K (-4.2%) | 214.2K -13.4K (-5.9%) | 0.08% -0.005 pp | 0.00% +0.000 pp | USD2.57 +61.9% | 19 qtrs — |
| 38 | SANCTUARY ADVISORS, LLC | 45.8K -4.8K (-9.5%) | 190.5K -23.8K (-11.1%) | 0.07% -0.008 pp | 0.00% 0.000 pp | USD2.35 +77.0% | 7 qtrs — |
| 39 | UBS GROUP AG | 39.1K +7.6K (+24.1%) | 162.7K +29.2K (+21.9%) | 0.06% +0.011 pp | 0.00% +0.000 pp | USD2.38 +74.8% | 9 qtrs — |
| 40 | BLAIR WILLIAM & CO/IL | 37.9K +— (+0.0%) | 157.6K -2.8K (-1.8%) | 0.06% -0.001 pp | 0.00% +0.000 pp | USD1.31 +217.6% | 15 qtrs — |
| 41 | LIDO ADVISORS, LLC | 36.3K +— (+0.0%) | 153.8K +— (+0.0%) | 0.06% -0.001 pp | 0.00% +0.000 pp | USD4.24 -1.9% | 4 qtrs — |
| 42 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 30.0K -15.0K (-33.4%) | 124.7K -65.8K (-34.5%) | 0.05% -0.024 pp | 0.00% +0.000 pp | USD4.24 -1.9% | 27 qtrs — |
| 43 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 35.2K -20.0 (-0.1%) | 121.5K -46.6K (-27.7%) | 0.05% -0.001 pp | 0.00% 0.000 pp | USD1.86 +123.7% | 10 qtrs — |
| 44 | CITADEL ADVISORS LLC | 27.5K -44.8K (-62.0%) | 114.4K -191.8K (-62.6%) | 0.04% -0.071 pp | 0.00% +0.000 pp | USD1.56 +166.7% | 13 qtrs — |
| 45 | SOLUTIONS 4 WEALTH, LTD | 25.4K +— (+0.0%) | 105.6K -1.9K (-1.8%) | 0.04% -0.001 pp | 0.16% -0.007 pp | USD1.66 +150.6% | 9 qtrs — |
| 46 | BANK OF AMERICA CORP /DE/ | 25.1K -264.0 (-1.0%) | 104.3K -3.0K (-2.8%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD3.18 +30.8% | 49 qtrs — |
| 47 | GLADSTONE INSTITUTIONAL ADVISORY LLC | 23.9K -750.0 (-3.0%) | 99.4K -5.0K (-4.8%) | 0.04% -0.002 pp | 0.00% 0.000 pp | USD2.58 +61.2% | 6 qtrs — |
| 48 | BALYASNY ASSET MANAGEMENT L.P. | 21.7K +21.7K (+100.0%) | 90.3K +90.3K (+100.0%) | 0.03% +0.034 pp | 0.00% +0.000 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 49 | INSPIRE ADVISORS, LLC | 21.1K +— (+0.0%) | 87.8K -1.6K (-1.8%) | 0.03% 0.000 pp | 0.01% -0.001 pp | USD1.49 +179.2% | 9 qtrs — |
| 50 | CAHABA WEALTH MANAGEMENT, INC. | 21.0K +— (+0.0%) | 87.4K -1.6K (-1.8%) | 0.03% 0.000 pp | 0.01% 0.000 pp | USD1.28 +225.0% | 5 qtrs — |
| 51 | SUMMIT TRAIL ADVISORS, LLC | 20.0K +— (+0.0%) | 83.2K -1.5K (-1.8%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD2.11 +97.2% | 3 qtrs — |
| 52 | MARINER, LLC | 19.9K -7.7K (-27.8%) | 82.8K -34.0K (-29.1%) | 0.03% -0.013 pp | 0.00% 0.000 pp | USD2.11 +97.2% | 14 qtrs — |
| 53 | STRATOS WEALTH PARTNERS, LTD. | 19.1K -11.0K (-36.5%) | 79.4K -47.9K (-37.6%) | 0.03% -0.018 pp | 0.00% -0.001 pp | USD3.52 +18.2% | 47 qtrs — |
| 54 | LIGHTHOUSE INVESTMENT PARTNERS, LLC | 18.9K +18.9K (+100.0%) | 78.6K +78.6K (+100.0%) | 0.03% +0.029 pp | 0.00% +0.002 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 55 | MANGROVE PARTNERS | 18.8K +18.8K (+100.0%) | 78.1K +78.1K (+100.0%) | 0.03% +0.029 pp | 0.01% +0.006 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 56 | RUSSELL INVESTMENTS GROUP, LTD. | 18.1K +17.9K (+9,997.2%) | 75.2K +74.4K (+9,819.3%) | 0.03% +0.028 pp | 0.00% +0.000 pp | USD4.13 +0.7% | 6 qtrs — |
| 57 | TWO SIGMA INVESTMENTS, LP | 16.6K -35.0 (-0.2%) | 69.1K -1.4K (-2.0%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD4.24 -1.9% | 2 qtrs — |
| 58 | SQUAREPOINT OPS LLC | 16.5K +16.5K (+100.0%) | 68.5K +68.5K (+100.0%) | 0.03% +0.026 pp | 0.00% +0.000 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 59 | JEFFERIES FINANCIAL GROUP INC. | 16.4K -865.0 (-5.0%) | 68.4K -4.9K (-6.7%) | 0.03% -0.002 pp | 0.00% +0.000 pp | USD4.24 -1.9% | 2 qtrs — |
| 60 | CETERA INVESTMENT ADVISERS | 14.2K +14.2K (+100.0%) | 59.2K +59.2K (+100.0%) | 0.02% +0.022 pp | 0.00% +0.000 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 61 | RAYMOND JAMES FINANCIAL INC | 13.7K +13.7K (+100.0%) | 57.1K +57.1K (+100.0%) | 0.02% +0.021 pp | 0.00% +0.000 pp | USD4.16 +0.0% | 5 qtrs — |
| 62 | SIG BROKERAGE, LP | 13.6K -2.1K (-13.5%) | 56.6K -10.0K (-15.0%) | 0.02% -0.004 pp | 0.00% 0.000 pp | USD1.22 +241.0% | 4 qtrs — |
| 63 | BNP PARIBAS ARBITRAGE, SNC | 13.5K +13.4K (+9,767.2%) | 56.2K +55.7K (+9,595.7%) | 0.02% +0.021 pp | 0.00% +0.000 pp | USD4.14 +0.5% | 7 qtrs — |
| 64 | ARGYLE CAPITAL PARTNERS, LLC | 13.4K +— (+0.0%) | 55.6K -1.0K (-1.8%) | 0.02% 0.000 pp | 0.04% +0.000 pp | USD1.29 +222.5% | 5 qtrs — |
| 65 | ARCHER INVESTMENT CORP | 12.9K +1.9K (+17.2%) | 53.6K +7.1K (+15.1%) | 0.02% +0.003 pp | 0.01% +0.002 pp | USD4.23 -1.7% | 2 qtrs — |
| 66 | FMR LLC | 12.8K +100.0 (+0.8%) | 53.3K -537.0 (-1.0%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD1.41 +195.0% | 6 qtrs — |
| 67 | COLONY GROUP, LLC | 12.6K +334.0 (+2.7%) | 52.4K +469.0 (+0.9%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD2.79 +49.1% | 6 qtrs — |
| 68 | CREATIVE PLANNING | 11.3K +880.0 (+8.5%) | 46.9K +2.9K (+6.6%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD4.23 -1.7% | 2 qtrs — |
| 69 | CITIGROUP INC | 11.2K +11.1K (+8,153.7%) | 46.7K +46.1K (+8,006.9%) | 0.02% +0.017 pp | 0.00% +0.000 pp | USD4.15 +0.2% | 9 qtrs — |
| 70 | JPMORGAN CHASE & CO | 11.0K -4.4K (-28.6%) | 45.9K -19.6K (-29.9%) | 0.02% -0.007 pp | 0.00% +0.000 pp | USD2.41 +72.6% | 11 qtrs — |
| 71 | STOCK YARDS BANK & TRUST CO | 10.5K +— (+0.0%) | 43.7K -788.0 (-1.8%) | 0.02% 0.000 pp | 0.00% 0.000 pp | USD1.61 +158.4% | 16 qtrs — |
| 72 | INVESCO LTD. | 10.3K +10.3K (+100.0%) | 42.8K +42.8K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.000 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 73 | ATWOOD & PALMER INC | 10.0K +— (+0.0%) | 41.6K -750.0 (-1.8%) | 0.02% 0.000 pp | 0.00% 0.000 pp | USD4.24 -1.9% | 2 qtrs — |
| 74 | RONALD BLUE TRUST, INC. | 7.0K +— (+0.0%) | 29.1K -525.0 (-1.8%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD1.47 +183.0% | 15 qtrs — |
| 75 | TOWER RESEARCH CAPITAL LLC (TRC) | 6.0K +6.0K (+100.0%) | 25.0K +25.0K (+100.0%) | 0.01% +0.009 pp | 0.00% +0.001 pp | USD4.16 +0.0% | 31 qtrs — |
| 76 | ROYAL BANK OF CANADA | 6.2K +5.7K (+1,197.3%) | 25.0K +23.0K (+1,150.0%) | 0.01% +0.009 pp | 0.00% +0.000 pp | USD4.00 +4.0% | 9 qtrs — |
| 77 | CLEARSTEAD ADVISORS, LLC | 6.0K +— (+0.0%) | 25.0K -450.0 (-1.8%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD1.49 +179.2% | 11 qtrs — |
| 78 | SIMPLEX TRADING, LLC | 5.6K -61.8K (-91.7%) | 23.2K -261.8K (-91.9%) | 0.01% -0.097 pp | 0.00% 0.000 pp | USD2.83 +47.0% | 17 qtrs — |
| 79 | CORECAP ADVISORS, LLC | 4.6K +— (+0.0%) | 19.1K -345.0 (-1.8%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD2.63 +58.2% | 8 qtrs — |
| 80 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 4.4K +— (+0.0%) | 18.2K -329.0 (-1.8%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD4.24 -1.9% | 2 qtrs — |
| 81 | WELLS FARGO & COMPANY/MN | 4.1K +— (+0.0%) | 17.0K -308.0 (-1.8%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD2.09 +99.0% | 50 qtrs — |
| 82 | SOUND INCOME STRATEGIES, LLC | 3.0K +— (+0.0%) | 9.1K -5.1K (-36.0%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD2.10 +98.1% | 12 qtrs — |
| 83 | ACTIVEST WEALTH MANAGEMENT | 2.0K +— (+0.0%) | 8.3K -150.0 (-1.8%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD2.35 +77.0% | 7 qtrs — |
| 84 | SIGNATUREFD, LLC | 1.7K +114.0 (+7.4%) | 6.9K +358.0 (+5.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.23 -1.7% | 2 qtrs — |
| 85 | MAI CAPITAL MANAGEMENT | 1.0K +— (+0.0%) | 4.2K -75.0 (-1.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.29 +222.5% | 5 qtrs — |
| 86 | NISA INVESTMENT ADVISORS, LLC | 716.00 +— (+0.0%) | 3.0K -53.0 (-1.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.22 +241.0% | 4 qtrs — |
| 87 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 600.00 +600.0 (+100.0%) | 2.5K +2.5K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 88 | GLOBAL RETIREMENT PARTNERS, LLC | 250.00 +— (+0.0%) | 1.0K -19.0 (-1.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.11 +97.2% | 3 qtrs — |
| 89 | CWM, LLC | 306.00 -24.0 (-7.3%) | 1.0K +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.58 +163.3% | 4 qtrs — |
| 90 | CIBC PRIVATE WEALTH GROUP, LLC | 200.00 +200.0 (+100.0%) | 832.00 +832.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 91 | HARBOUR INVESTMENTS, INC. | 150.00 +150.0 (+100.0%) | 624.00 +624.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 92 | FORTITUDE FAMILY OFFICE, LLC | 90.00 +90.0 (+100.0%) | 374.00 +374.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.16 +0.0% | 1 qtrs NEW |
| 93 | OPTIVER HOLDING B.V. | 18.00 +— (+0.0%) | 75.00 -1.0 (-1.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.22 -1.4% | 2 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 35 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Horizon Kinetics Medical ETF MEDX | 1.03% | 190.7K | 0.85% |
| 2 | iShares Micro-Cap ETF IWC | 0.04% | 652.0K | 0.60% |
| 3 | iShares Russell 2000 Growth ETF IWO | 0.01% | 1.26M | 0.24% |
| 4 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 216.2K | 0.30% |
| 5 | Global X - Russell 2000 ETF RSSL | 0.01% | 90.9K | 0.08% |
| 6 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 19.6K | 0.25% |
| 7 | iShares Russell 2000 BuyWrite ETF IWMW | 0.00% | 2.7K | 0.39% |
| 8 | iShares Russell 2000 ETF IWM | 0.00% | 3.94M | 0.19% |
| 9 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.00% | 25.7K | 0.36% |
| 10 | iShares Russell 2000 Value ETF IWN | 0.00% | 453.5K | 0.24% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.25
Bearish
Ratio by volume
0.50
Neutral
Buys
3
Sells
12
Shares acquired
204.0K
Shares disposed
408.0K
Cash buys
—
Cash sales
9.00
Net activity
-204,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-12 | Brem Henry | Director | A-Award | A | Stock option (right to buy) | 60,000 | 3.16 | 189.6K | 60,000 | D | ↗ |
| 2026-02-06 | ELDRED KARY | Director | P-Purchase | A | Common Stock | 300 | 2.70 | 810.00 | 65,682 | D | ↗ |
| 2026-01-16 | Zordani Richard A. Jr. | Director | A-Award | A | Stock option (right to buy) | 60,000 | 3.04 | 182.4K | 60,000 | D | ↗ |
| 2026-01-16 | Uihlein Richard E | Director / 10% Owner | A-Award | A | Stock option (right to buy) | 60,000 | 3.04 | 182.4K | 60,000 | D | ↗ |
| 2026-01-16 | Shlevin Harold H. | Director | A-Award | A | Stock option (right to buy) | 60,000 | 3.04 | 182.4K | 60,000 | D | ↗ |
| 2026-01-16 | Schwartz Elissa J. | Director | A-Award | A | Stock option (right to buy) | 60,000 | 3.04 | 182.4K | 60,000 | D | ↗ |
| 2026-01-16 | OMENN GILBERT S | Director | A-Award | A | Stock option (right to buy) | 60,000 | 0.00 | — | 60,000 | D | ↗ |
| 2026-01-16 | LEWIS JOEL | Director / Officer | A-Award | A | Stock option (right to buy) | 84,000 | 3.04 | 255.4K | 65,000 | D | ↗ |
| 2026-01-16 | Jamil Khurram | Officer | A-Award | A | Restricted Stock Unit | 100,000 | 0.00 | — | 100,000 | D | ↗ |
| 2026-01-16 | FREEMAN KEVIN D | Director | A-Award | A | Stock option (right to buy) | 60,000 | 3.04 | 182.4K | 60,000 | D | ↗ |
| 2026-01-16 | ELDRED KARY | Director | A-Award | A | Stock option (right to buy) | 60,000 | 3.04 | 182.4K | 60,000 | D | ↗ |
| 2026-01-16 | CARSON BENJAMIN SR | Director | A-Award | A | Stock option (right to buy) | 60,000 | 3.04 | 182.4K | 60,000 | D | ↗ |
| 2026-01-16 | CALLICUTT JACK W | Officer | A-Award | A | Restricted Stock Unit | 100,000 | 0.00 | — | 100,000 | D | ↗ |
| 2026-01-16 | AMELIO GILBERT F | Director | A-Award | A | Stock option (right to buy) | 60,000 | 3.04 | 182.4K | 60,000 | D | ↗ |
| 2026-01-06 | LEWIS JOEL | Director / Officer | S-Sale | D | Common Stock | 37,698 | 3.58 | 134.9K | 832,592 | D | ↗ |
| 2026-01-06 | Jamil Khurram | Officer | S-Sale | D | Common Stock | 21,446 | 3.65 | 78.2K | 0 | D | ↗ |
| 2026-01-06 | CALLICUTT JACK W | Officer | S-Sale | D | Common Stock | 20,354 | 3.67 | 74.7K | 7,614 | D | ↗ |
| 2026-01-05 | LEWIS JOEL | Director / Officer | — | D | Common Stock | 56,332 | 3.88 | 218.6K | 776,260 | D | ↗ |
| 2026-01-05 | Jamil Khurram | Officer | S-Sale | D | Common stock | 25,499 | 3.90 | 99.4K | 21,446 | D | ↗ |
| 2026-01-05 | CALLICUTT JACK W | Officer | S-Sale | D | Common Stock | 25,732 | 3.90 | 100.3K | 27,968 | D | ↗ |
| 2026-01-02 | LEWIS JOEL | Director / Officer | S-Sale | D | Common Stock | 18,571 | 4.20 | 77.9K | 898,021 | D | ↗ |
| 2026-01-02 | Jamil Khurram | Officer | S-Sale | D | Common Stock | 13,055 | 4.20 | 54.8K | 46,945 | D | ↗ |
| 2026-01-02 | CALLICUTT JACK W | Officer | S-Sale | D | Common Stock | 13,914 | 4.20 | 58.4K | 53,700 | D | ↗ |
| 2026-01-01 | Jamil Khurram | Officer | M-Exempt | D | Restricted Stock Unit | 60,000 | 0.00 | — | 0 | D | ↗ |
| 2026-01-01 | CALLICUTT JACK W | Officer | M-Exempt | D | Restricted Stock Unit | 60,000 | 0.00 | — | 0 | D | ↗ |
| 2025-12-31 | Jamil Khurram | Officer | S-Sale | D | Common Stock | 8,125 | 4.07 | 33.1K | 0 | D | ↗ |
| 2025-12-23 | FREEMAN KEVIN D | Director | P-Purchase | A | Common Stock | 5,500 | 3.55 | 19.5K | 55,269 | D | ↗ |
| 2025-12-23 | ELDRED KARY | Director | P-Purchase | A | Common Stock | 700 | 3.73 | 2.6K | 65,382 | D | ↗ |
| 2025-12-17 | Shlevin Harold H. | Director | M-Exempt | D | Stock Option (right to buy) | 20,000 | 1.98 | 39.6K | 0 | D | ↗ |
| 2025-12-17 | LEWIS JOEL | Director / Officer | M-Exempt | D | Stock option (right to buy) | 7,829 | 2.86 | 22.4K | 32,171 | D | ↗ |
| 2025-12-17 | Jamil Khurram | Officer | M-Exempt | A | Common Stock | 8,500 | 2.50 | 21.3K | 8,500 | D | ↗ |
| 2025-12-16 | 10X Fund, L.P. | 10% Owner | S-Sale | D | Common Stock | 30,681 | 6.66 | 204.3K | 5,614,457 | D | ↗ |
| 2025-12-15 | Shlevin Harold H. | Director | M-Exempt | A | Common Stok | 8,417 | 4.16 | 35.0K | 19,623 | D | ↗ |
| 2025-12-12 | Shlevin Harold H. | Director | M-Exempt | A | Common Stock | 19,793 | 4.16 | 82.3K | 30,999 | D | ↗ |
| 2025-12-09 | Shlevin Harold H. | Director | M-Exempt | D | Stock Option (right to buy) | 16,790 | 4.16 | 69.8K | 73,210 | D | ↗ |
| 2025-12-08 | Shlevin Harold H. | Director | M-Exempt | D | Stock Option (right to buy) | 20,000 | 1.11 | 22.2K | 20,000 | D | ↗ |
| 2025-12-03 | 10X Fund, L.P. | 10% Owner | S-Sale | D | Common Stock | 132,069 | 5.73 | 756.8K | 5,670,138 | D | ↗ |
| 2025-12-02 | 10X Fund, L.P. | 10% Owner | S-Sale | D | Common Stock | 30,000 | 5.47 | 164.1K | 5,802,207 | D | ↗ |
| 2025-11-24 | 10X Fund, L.P. | 10% Owner | J-Other | D | Common Stock | 24,000 | 0.00 | — | 5,645,138 | D | ↗ |
| 2025-11-18 | LEWIS JOEL | Director / Officer | M-Exempt | D | Stock option (right to buy) | 6,783 | 2.39 | 16.2K | 0 | D | ↗ |
| 2025-11-18 | CALLICUTT JACK W | Officer | M-Exempt | D | Common stock (right to buy) | 18,190 | 1.11 | 20.2K | 0 | D | ↗ |
| 2025-11-17 | LEWIS JOEL | Director / Officer | M-Exempt | D | Stock option (right to buy) | 15,680 | 2.39 | 37.5K | 6,783 | D | ↗ |
| 2025-11-17 | CALLICUTT JACK W | Officer | M-Exempt | A | Common stock | 2,323 | 1.23 | 2.9K | 9,937 | D | ↗ |
| 2025-11-13 | Jamil Khurram | Officer | M-Exempt | A | Common Stock | 41,500 | 2.20 | 91.3K | 45,979 | D | ↗ |
| 2025-11-11 | 10X Fund, L.P. | 10% Owner | S-Sale | D | Common Stock | 40,000 | 5.25 | 210.0K | 5,832,207 | D | ↗ |
| 2025-11-10 | LEWIS JOEL | Director / Officer | S-Sale | D | Common Stock | 1,867 | 6.03 | 11.3K | 832,592 | D | ↗ |
| 2025-11-10 | CALLICUTT JACK W | Officer | M-Exempt | A | Common stock | 1,880 | 1.98 | 3.7K | 9,694 | D | ↗ |
| 2025-11-05 | LEWIS JOEL | Director / Officer | M-Exempt | D | Stock option (right to buy) | 200 | 2.39 | 478.00 | 24,230 | D | ↗ |
| 2025-11-05 | CALLICUTT JACK W | Officer | M-Exempt | D | Stock option (right to buy) | 200 | 1.98 | 396.00 | 39,586 | D | ↗ |
| 2025-11-04 | LEWIS JOEL | Director / Officer | S-Sale | D | Common Stock | 14,420 | 6.07 | 87.5K | 832,592 | D | ↗ |
| 2025-11-04 | CALLICUTT JACK W | Officer | M-Exempt | A | Common stock | 10,741 | 1.72 | 18.5K | 18,355 | D | ↗ |
| 2025-11-03 | LEWIS JOEL | Director / Officer | M-Exempt | D | Stock option (right to buy) | 1,300 | 2.39 | 3.1K | 38,950 | D | ↗ |
| 2025-11-03 | CALLICUTT JACK W | Officer | M-Exempt | D | Stock option (right to buy) | 1,250 | 1.72 | 2.2K | 63,750 | D | ↗ |
| 2025-10-22 | 10X Fund, L.P. | 10% Owner | S-Sale | D | Common Stock | 20,000 | 4.93 | 98.6K | 5,902,207 | D | ↗ |
| 2025-09-12 | LEWIS JOEL | Director / Officer | M-Exempt | A | Common Stock | 14,000 | 2.39 | 33.5K | 846,592 | D | ↗ |
| 2025-09-12 | CALLICUTT JACK W | Officer | M-Exempt | A | Common Stock | 8,706 | 1.37 | 11.9K | 16,320 | D | ↗ |
| 2025-07-21 | ELDRED KARY | Director | P-Purchase | A | Common Stock | 1,000 | 2.93 | 2.9K | 64,682 | D | ↗ |
| 2025-07-17 | FREEMAN KEVIN D | Director | P-Purchase | A | Common Stock | 5,000 | 2.90 | 14.5K | 49,769 | D | ↗ |
| 2025-06-06 | CZIRR JAMES C | 10% Owner | M-Exempt | D | Stock Option (right to buy) | 30,000 | 2.86 | 85.8K | 190,000 | D | ↗ |
| 2025-03-31 | CZIRR JAMES C | 10% Owner | J-Other | A | Common Stock | 1,000 | 6.00 | 6.0K | 722,416 | D | ↗ |
| 2025-03-03 | LEWIS JOEL | Director / Officer | A-Award | D | Common Stock | 56,420 | 1.57 | 88.6K | 832,592 | D | ↗ |
| 2025-02-04 | CZIRR JAMES C | 10% Owner | G-Gift | D | Common Stock | 10,000 | 0.00 | — | 721,416 | D | ↗ |
| 2025-02-03 | CZIRR JAMES C | 10% Owner | G-Gift | D | Common Stock | 10,000 | 0.00 | — | 731,416 | D | ↗ |
| 2025-01-23 | Zordani Richard A. Jr. | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 1.23 | 73.8K | 60,000 | D | ↗ |
| 2025-01-23 | Uihlein Richard E | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 60,000 | 1.23 | 73.8K | 60,000 | D | ↗ |
| 2025-01-23 | Shlevin Harold H. | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 1.23 | 73.8K | 60,000 | D | ↗ |
| 2025-01-23 | Schwartz Elissa J. | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 1.23 | 73.8K | 60,000 | D | ↗ |
| 2025-01-23 | Rubin Marc | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 1.23 | 73.8K | 60,000 | D | ↗ |
| 2025-01-23 | OMENN GILBERT S | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 1.23 | 73.8K | 60,000 | D | ↗ |
| 2025-01-23 | LEWIS JOEL | Director / Officer | A-Award | A | Restricted Stock Unit | 84,000 | 0.00 | — | 84,000 | D | ↗ |
| 2025-01-23 | Jamil Khurram | Officer | A-Award | A | Restricted Stock Unit | 60,000 | 0.00 | — | 60,000 | D | ↗ |
| 2025-01-23 | FREEMAN KEVIN D | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 1.23 | 73.8K | 60,000 | D | ↗ |
| 2025-01-23 | ELDRED KARY | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 1.23 | 73.8K | 60,000 | D | ↗ |
| 2025-01-23 | CARSON BENJAMIN SR | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 1.23 | 73.8K | 60,000 | D | ↗ |
| 2025-01-23 | CALLICUTT JACK W | Officer | A-Award | A | Restricted Stock Unit | 60,000 | 0.00 | — | 60,000 | D | ↗ |
| 2024-12-31 | CZIRR JAMES C | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-31 | 10X Fund, L.P. | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-30 | Shlevin Harold H. | Director | P-Purchase | A | Common Stock | 6,500 | 1.16 | 7.5K | 15,206 | D | ↗ |
| 2024-12-24 | Zordani Richard A. Jr. | Director | P-Purchase | A | Common Stock | 10,000 | 0.82 | 8.2K | 42,083 | D | ↗ |
| 2024-12-24 | FREEMAN KEVIN D | Director | P-Purchase | A | Common Stock | 10,000 | 0.81 | 8.1K | 44,769 | D | ↗ |
| 2024-12-24 | ELDRED KARY | Director | P-Purchase | A | Common Stock | 13,469 | 0.82 | 11.0K | 63,682 | D | ↗ |
| 2024-12-23 | LEWIS JOEL | Director / Officer | S-Sale | D | Common Stock | 56,000 | 0.89 | 49.6K | 897,012 | D | ↗ |
| 2024-12-23 | Jamil Khurram | Officer | M-Exempt | A | Restricted Stock Units | 40,000 | 0.00 | — | 0 | D | ↗ |
| 2024-12-23 | CALLICUTT JACK W | Officer | M-Exempt | A | Common Stock | 40,000 | 0.00 | — | 47,614 | D | ↗ |
| 2024-10-23 | ELDRED KARY | Director | P-Purchase | A | Common Stock | 500 | 2.60 | 1.3K | 50,213 | D | ↗ |
| 2024-10-17 | FREEMAN KEVIN D | Director | P-Purchase | A | Common Stock | 1,300 | 2.64 | 3.4K | 34,769 | D | ↗ |
| 2024-10-16 | FREEMAN KEVIN D | Director | P-Purchase | A | Common Stock | 5,000 | 2.70 | 13.5K | 80,000 | I | ↗ |
| 2024-08-23 | Zordani Richard A. Jr. | Director | P-Purchase | A | Common Stock | 1,759 | 2.30 | 4.0K | 32,083 | — | ↗ |
| 2024-08-22 | Zordani Richard A. Jr. | Director | P-Purchase | A | Common Stock | 741 | 2.30 | 1.7K | 30,324 | — | ↗ |
| 2024-08-02 | Jamil Khurram | Officer | — | D | Restricted Stock Unit | 30,000 | 0.00 | — | 0 | — | ↗ |
| 2024-08-01 | Jamil Khurram | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 2.50 | 250.0K | 100,000 | — | ↗ |
| 2024-07-22 | ELDRED KARY | Director | P-Purchase | A | Common Stock | 400 | 2.39 | 956.00 | 49,713 | — | ↗ |
| 2024-06-20 | FREEMAN KEVIN D | Director | P-Purchase | A | Common Stock | 2,500 | 2.38 | 5.9K | 28,469 | — | ↗ |
| 2024-04-30 | Zordani Richard A. Jr. | Director | P-Purchase | A | Common Stock | 1,000 | 3.52 | 3.5K | 1,000 | — | ↗ |
| 2024-04-24 | LEWIS JOEL | Director / Officer | P-Purchase | A | Common Stock | 1,000 | 3.39 | 3.4K | 2,000 | — | ↗ |
| 2024-04-23 | CZIRR JAMES C | 10% Owner | S-Sale | D | Common Stock | 3,677 | 3.06 | 11.3K | 5,922,207 | — | ↗ |
| 2024-04-22 | FREEMAN KEVIN D | Director | P-Purchase | A | Common Stock | 2,500 | 2.98 | 7.5K | 25,969 | — | ↗ |
| 2024-04-22 | CZIRR JAMES C | 10% Owner | S-Sale | D | Common Stock | 21,323 | 3.06 | 65.2K | 5,925,884 | — | ↗ |
| 2024-04-09 | FREEMAN KEVIN D | Director | W-Will | A | Common Stock | 2,063 | 0.00 | — | 18,063 | — | ↗ |
| 2024-03-01 | LEWIS JOEL | Director / Officer | A-Award | D | Common Stock | 152,584 | 1.96 | 299.1K | 897,716 | — | ↗ |
| 2024-01-24 | Zordani Richard A. Jr. | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.72 | 86.0K | 50,000 | — | ↗ |
| 2024-01-24 | Uihlein Richard E | Director / 10% Owner | A-Award | A | Common Stock | 23,256 | 1.72 | 40.0K | 10,268,751 | — | ↗ |
| 2024-01-24 | Schwartz Elissa J. | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.72 | 86.0K | 50,000 | — | ↗ |
| 2024-01-24 | Rubin Marc | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.72 | 86.0K | 50,000 | — | ↗ |
| 2024-01-24 | OMENN GILBERT S | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.72 | 86.0K | 50,000 | — | ↗ |
| 2024-01-24 | LEWIS JOEL | Director / Officer | A-Award | A | Restricted Stock Unit | 56,000 | 0.00 | — | 56,000 | — | ↗ |
| 2024-01-24 | FREEMAN KEVIN D | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.72 | 86.0K | 50,000 | — | ↗ |
| 2024-01-24 | ELDRED KARY | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.72 | 86.0K | 50,000 | — | ↗ |
| 2024-01-24 | CARSON BENJAMIN SR | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.72 | 86.0K | 50,000 | — | ↗ |
| 2024-01-24 | CALLICUTT JACK W | Officer | A-Award | A | Stock Option (right to buy) | 65,000 | 1.72 | 111.8K | 65,000 | — | ↗ |
| 2024-01-24 | Boudes Pol F | Officer | A-Award | A | Restricted Stock Unit | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2024-01-24 | AMELIO GILBERT F | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.72 | 86.0K | 50,000 | — | ↗ |
| 2024-01-16 | ELDRED KARY | Director | P-Purchase | A | Common Stock | 500 | 1.79 | 892.90 | 49,313 | — | ↗ |
| 2023-12-31 | CZIRR JAMES C | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-29 | LEWIS JOEL | Director / Officer | A-Award | A | Common Stock | 11,606 | 1.66 | 19.3K | 1,042,300 | — | ↗ |
| 2023-12-15 | LEWIS JOEL | Director / Officer | A-Award | A | Common Stock | 12,042 | 1.60 | 19.3K | 1,030,694 | — | ↗ |
| 2023-12-07 | CARSON BENJAMIN SR | Director | — | D | Common Stock Options | 100,000 | 2.23 | 223.0K | 0 | — | ↗ |
| 2023-11-30 | LEWIS JOEL | Director / Officer | A-Award | A | Common Stock | 9,880 | 1.95 | 19.3K | 1,018,652 | — | ↗ |
| 2023-11-15 | LEWIS JOEL | Director / Officer | A-Award | A | Common Stock | 10,303 | 1.87 | 19.3K | 1,008,772 | — | ↗ |
| 2023-10-31 | LEWIS JOEL | Director / Officer | A-Award | A | Common Stock | 9,444 | 2.04 | 19.3K | 998,469 | — | ↗ |
| 2023-10-13 | LEWIS JOEL | Director / Officer | A-Award | A | Common Stock | 9,585 | 2.01 | 19.3K | 989,025 | — | ↗ |
| 2023-09-29 | LEWIS JOEL | Director / Officer | A-Award | A | Common Stock | 10,035 | 1.92 | 19.3K | 979,440 | — | ↗ |
| 2023-09-26 | Uihlein Richard E | Director / 10% Owner | M-Exempt | D | Common Stock Purchase Warrant (right to buy) | 200,000 | 3.00 | 600.0K | 0 | — | ↗ |
| 2023-09-15 | LEWIS JOEL | Director / Officer | A-Award | A | Common Stock | 10,947 | 1.76 | 19.3K | 969,405 | — | ↗ |
| 2023-08-31 | LEWIS JOEL | Director / Officer | A-Award | A | Common Stock | 11,010 | 1.75 | 19.3K | 958,458 | — | ↗ |
| 2023-08-15 | LEWIS JOEL | Director / Officer | A-Award | A | Common Stock | 12,042 | 1.60 | 19.3K | 947,448 | — | ↗ |
| 2023-07-31 | LEWIS JOEL | Director / Officer | A-Award | A | Common Stock | 12,844 | 1.50 | 19.3K | 935,406 | — | ↗ |
| 2023-07-19 | ELDRED KARY | Director | P-Purchase | A | Common Stock | 1,598 | 1.79 | 2.9K | 48,813 | — | ↗ |
| 2023-07-14 | LEWIS JOEL | Director / Officer | A-Award | A | Common Stock | 11,820 | 1.63 | 19.3K | 922,562 | — | ↗ |
| 2023-06-30 | LEWIS JOEL | Director / Officer | A-Award | A | Common Stock | 13,380 | 1.44 | 19.3K | 911 | — | ↗ |
| 2023-06-15 | LEWIS JOEL | Director / Officer | A-Award | A | Common Stock | 13,196 | 1.46 | 19.3K | 897,362 | — | ↗ |
| 2023-05-31 | LEWIS JOEL | Director / Officer | A-Award | A | Common Stock | 12,272 | 1.57 | 19.3K | 884,166 | — | ↗ |
| 2023-05-15 | LEWIS JOEL | Director / Officer | A-Award | A | Common Stock | 11,748 | 1.64 | 19.3K | 871,894 | — | ↗ |
| 2023-04-28 | LEWIS JOEL | Director / Officer | A-Award | A | Common Stock | 10,947 | 1.76 | 19.3K | 860,146 | — | ↗ |
| 2023-04-14 | LEWIS JOEL | Director / Officer | A-Award | A | Common Stock | 9,585 | 2.01 | 19.3K | 849,199 | — | ↗ |
| 2023-03-31 | LEWIS JOEL | — | A-Award | A | Common Stock | 9,175 | 2.10 | 19.3K | 839,614 | — | ↗ |
| 2023-03-15 | LEWIS JOEL | — | A-Award | A | Common Stock | 10,140 | 1.90 | 19.3K | 830,439 | — | ↗ |
| 2023-03-01 | LEWIS JOEL | — | F-InKind | D | Common Stock | 75,529 | 2.07 | 156.3K | 820,299 | — | ↗ |
| 2023-02-28 | LEWIS JOEL | — | A-Award | A | Common Stock | 9,308 | 2.07 | 19.3K | 895,828 | — | ↗ |
| 2023-02-21 | ELDRED KARY | — | P-Purchase | A | Common Stock | 1,000 | 1.59 | 1.6K | 47,215 | — | ↗ |
| 2023-02-16 | LEWIS JOEL | — | P-Purchase | A | Common Stock | 1,000 | 1.52 | 1.5K | 1,000 | — | ↗ |
| 2023-02-15 | LEWIS JOEL | — | A-Award | A | Common Stock | 13,380 | 1.44 | 19.3K | 886,520 | — | ↗ |
| 2023-02-07 | LEWIS JOEL | — | A-Award | A | Common Stock | 143,836 | 1.43 | 205.7K | 873,140 | — | ↗ |
| 2023-01-31 | LEWIS JOEL | Director | A-Award | A | Common Stock | 15,086 | 1.16 | 17.5K | 729,304 | — | ↗ |
| 2023-01-26 | Zordani Richard A. Jr. | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-01-26 | Uihlein Richard E | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-01-26 | Shlevin Harold H. | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-01-26 | Schwartz Elissa J. | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-01-26 | Rubin Marc | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-01-26 | OMENN GILBERT S | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-01-26 | LEWIS JOEL | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 0.00 | — | 70,000 | — | ↗ |
| 2023-01-26 | FREEMAN KEVIN D | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-01-26 | ELDRED KARY | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-01-26 | CZIRR JAMES C | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-01-26 | CALLICUTT JACK W | Director / Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2023-01-26 | Boudes Pol F | Director / Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2023-01-26 | AMELIO GILBERT F | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-01-25 | ELDRED KARY | Director | P-Purchase | A | Common Stock | 1,300 | 1.11 | 1.4K | 46,215 | — | ↗ |
| 2023-01-13 | LEWIS JOEL | Director | A-Award | A | Common Stock | 15,351 | 1.14 | 17.5K | 714,218 | — | ↗ |
| 2022-12-31 | 10X Fund, L.P. | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-30 | LEWIS JOEL | Director | A-Award | A | Common Stock | 15,487 | 1.13 | 17.5K | 698,867 | — | ↗ |
| 2022-12-21 | 10X Fund, L.P. | Director | — | D | Common Stock | 0 | 0.00 | — | 5,947,207 | — | ↗ |
| 2022-12-15 | LEWIS JOEL | Director | A-Award | A | Common Stock | 15,086 | 1.16 | 17.5K | 683,380 | — | ↗ |
| 2022-11-30 | LEWIS JOEL | Director | A-Award | A | Common Stock | 13,780 | 1.27 | 17.5K | 668,294 | — | ↗ |
| 2022-11-17 | CALLICUTT JACK W | Director / Officer | P-Purchase | A | Common Stock | 4,000 | 1.32 | 5.3K | 7,614 | — | ↗ |
| 2022-11-15 | LEWIS JOEL | Director | A-Award | A | Common Stock | 14,113 | 1.24 | 17.5K | 654,514 | — | ↗ |
| 2022-10-31 | LEWIS JOEL | Director | A-Award | A | Common Stock | 12,681 | 1.38 | 17.5K | 640,401 | — | ↗ |
| 2022-10-28 | FREEMAN KEVIN D | Director | P-Purchase | A | Common Stock | 10,000 | 1.41 | 14.1K | 75,000 | — | ↗ |
| 2022-10-14 | LEWIS JOEL | Director | A-Award | A | Common Stock | 10,802 | 1.62 | 17.5K | 627,720 | — | ↗ |
| 2022-09-30 | LEWIS JOEL | Director | A-Award | A | Common Stock | 10,736 | 1.79 | 19.2K | 616,918 | — | ↗ |
| 2022-09-15 | LEWIS JOEL | Director / Officer | A-Award | A | Common Stock | 9,777 | 1.79 | 17.5K | 606,182 | — | ↗ |
| 2022-08-31 | LEWIS JOEL | Director | A-Award | A | Common Stock | 9,211 | 1.90 | 17.5K | 596,405 | — | ↗ |
| 2022-08-15 | LEWIS JOEL | Director | A-Award | A | Common Stock | 8,028 | 2.18 | 17.5K | 587,194 | — | ↗ |
| 2022-07-29 | LEWIS JOEL | — | A-Award | A | Common Stock | 7,743 | 2.26 | 17.5K | 552,139 | — | ↗ |
| 2022-07-29 | 10X Fund, L.P. | Director | — | D | Common Stock | 0 | 0.00 | — | 6,044,858 | — | ↗ |
| 2022-07-28 | Zordani Richard A. Jr. | Director | P-Purchase | A | Common Stock | 5,000 | 2.50 | 12.5K | 29,583 | — | ↗ |
| 2022-07-27 | 10X Fund, L.P. | 10% Owner | S-Sale | D | Common Stock | 10,000 | 2.09 | 20.9K | 6,168,940 | — | ↗ |
| 2022-07-22 | CZIRR JAMES C | Director | S-Sale | D | Common Stock | 10,000 | 2.09 | 20.9K | 6,168,940 | — | ↗ |
| 2022-07-22 | 10X Fund, L.P. | 10% Owner | S-Sale | D | Common Stock | 10,000 | 2.09 | 20.9K | 6,168,940 | — | ↗ |
| 2022-07-15 | LEWIS JOEL | Director | A-Award | A | Common Stock | 10,606 | 1.65 | 17.5K | 544,396 | — | ↗ |
| 2022-06-30 | LEWIS JOEL | Director | A-Award | A | Common Stock | 13,359 | 1.31 | 17.5K | 533,790 | — | ↗ |
| 2022-06-15 | LEWIS JOEL | Director | A-Award | A | Common Stock | 13,780 | 1.29 | 17.8K | 520,431 | — | ↗ |
| 2022-05-31 | LEWIS JOEL | Director | A-Award | A | Common Stock | 13,566 | 1.29 | 17.5K | 506,651 | — | ↗ |
| 2022-05-19 | FREEMAN KEVIN D | Director | P-Purchase | A | Common Stock | 5,000 | 1.33 | 6.6K | 65,000 | — | ↗ |
| 2022-05-13 | LEWIS JOEL | Director | A-Award | A | Common Stock | 12,868 | 1.36 | 17.5K | 493,085 | — | ↗ |
| 2022-04-29 | LEWIS JOEL | Director | A-Award | A | Common Stock | 11,290 | 1.55 | 17.5K | 480,217 | — | ↗ |
| 2022-04-18 | FREEMAN KEVIN D | Director | P-Purchase | A | Common Stock | 5,000 | 1.71 | 8.6K | 60,000 | — | ↗ |
| 2022-04-15 | LEWIS JOEL | Director | A-Award | A | Common Stock | 10,057 | 1.74 | 17.5K | 468,927 | — | ↗ |
| 2022-04-04 | Zordani Richard A. Jr. | Director | P-Purchase | A | Common Stock | 5,000 | 1.61 | 8.0K | 24,583 | — | ↗ |
| 2022-03-31 | LEWIS JOEL | Director | A-Award | A | Common Stock | 10,870 | 1.61 | 17.5K | 458,870 | — | ↗ |
| 2022-03-15 | LEWIS JOEL | Director | A-Award | A | Common Stock | 10,057 | 1.74 | 17.5K | 448,000 | — | ↗ |
| 2022-02-28 | LEWIS JOEL | — | A-Award | A | Common Stock | 9,358 | 1.87 | 17.5K | 438 | — | ↗ |
| 2022-02-15 | LEWIS JOEL | — | A-Award | A | Common Stock | 8,454 | 2.07 | 17.5K | 428,585 | — | ↗ |
| 2022-02-02 | 10X Fund, L.P. | 10% Owner | S-Sale | D | Common Stock | 10,000 | 2.10 | 21.0K | 6,178,940 | — | ↗ |
| 2022-01-31 | LEWIS JOEL | — | A-Award | A | Common Stock | 112,263 | 1.93 | 216.7K | 420,131 | — | ↗ |
| 2022-01-24 | Zordani Richard A. Jr. | — | A-Award | A | Stock Option (right to buy) | 40,000 | 1.98 | 79.2K | 40,000 | — | ↗ |
| 2022-01-24 | Uihlein Richard E | — | A-Award | A | Stock Option (right to buy) | 40,000 | 1.98 | 79.2K | 40,000 | — | ↗ |
| 2022-01-24 | Shlevin Harold H. | — | A-Award | A | Stock Option (right to buy) | 40,000 | 1.98 | 79.2K | 40,000 | — | ↗ |
| 2022-01-24 | Schwartz Elissa J. | — | A-Award | A | Stock Option (right to buy) | 40,000 | 1.98 | 79.2K | 40,000 | — | ↗ |
| 2022-01-24 | Rubin Marc | — | A-Award | A | Stock Option (right to buy) | 40,000 | 1.98 | 79.2K | 40,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
65.83M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Joel Lewis, Chief Executive Officer & President | 620.2K | 312.0K | 202.6K | — | — | 54.9K | 1.19M | 17.03% | ↗ |
| 2 | 2024 | Khurram Jamil, M.D., Chief Medical Officer | 365.9K | 120.6K | 398.5K | — | — | 60.8K | 945.8K | 42.13% | ↗ |
| 3 | 2024 | Jack W. Callicutt, Chief Financial Officer | 397.3K | 120.0K | 144.7K | — | — | 54.9K | 716.9K | 20.19% | ↗ |
| 4 | 2023 | Joel Lewis, Chief Executive Officer President | 573.6K | 289.0K | — | 55.9K | — | 45.1K | 963.6K | 5.80% | ↗ |
| 5 | 2023 | Joel Lewis, Chief Executive Officer & President | 573.6K | 289.0K | 55.9K | — | — | 45.1K | 963.6K | 5.80% | ↗ |
| 6 | 2023 | Pol F. Boudes, M.D., Former Chief Medical Officer | 530.0K | 160.5K | — | 39.9K | — | 39.8K | 770.3K | 5.19% | ↗ |
| 7 | 2023 | Jack W. Callicutt, Chief Financial Officer | 364.0K | 110.4K | 39.9K | — | — | 47.1K | 561.4K | 7.12% | ↗ |
| 8 | 2022 | Joel Lewis, Chief Executive Officer President | 522.9K | 262.5K | — | 103.5K | — | 85.2K | 974.2K | 10.63% | ↗ |
| 9 | 2022 | Pol F. Boudes, M.D., Former Chief Medical Officer | 473.3K | 142.5K | — | 73.9K | — | 104.8K | 794.6K | 9.31% | ↗ |
| 10 | 2022 | Pol F. Boudes, M.D., Chief Medical Officer | 473.3K | 142.5K | — | 73.9K | — | 104.8K | 794.6K | 9.31% | ↗ |
| 11 | 2022 | Jack W. Callicutt, Chief Financial Officer | 318.5K | 96.0K | — | 73.9K | — | 78.1K | 566.6K | 13.05% | ↗ |
| 12 | 2021 | Joel Lewis, Chief Executive Officer President | 500.0K | 250.0K | — | 329.2K | — | 88.4K | 1.17M | 28.19% | ↗ |
| 13 | 2021 | Pol F. Boudes, M.D., Chief Medical Officer | 452.6K | 136.5K | — | 235.1K | — | 99.5K | 923.7K | 25.46% | ↗ |
| 14 | 2021 | Jack W. Callicutt, Chief Financial Officer | 302.1K | 90.6K | — | 235.1K | — | 78.1K | 705.9K | 33.31% | ↗ |
| 15 | 2020 | Pol F. Boudes, M.D., Chief Medical Officer | 367.1K | 210.0K | — | 419.5K | — | 85.9K | 1.08M | 38.75% | ↗ |
| 16 | 2020 | Harold H. Shlevin, Ph.D., Chief Executive Officer President | 375.6K | 335.0K | — | 154.3K | — | 54.5K | 919.3K | 16.78% | ↗ |
| 17 | 2020 | Joel Lewis, Chief Executive Officer President | 164.8K | 75.0K | — | 486.1K | — | 27.7K | 753.6K | 64.51% | ↗ |
| 18 | 2020 | Jack W. Callicutt, Chief Financial Officer | 300.7K | 236.1K | — | 110.2K | — | 73.5K | 720.4K | 15.30% | ↗ |
| 19 | 2019 | Harold H. Shlevin, Ph.D., Chief Executive Officer President | 500.0K | 465.6K | — | 268.2K | — | 72.7K | 1.31M | 20.53% | ↗ |
| 20 | 2019 | Harold H. Shlevin, Ph.D., Chief Executive Officer President | 500.0K | 465.6K | — | 268.2K | — | 72.7K | 1.31M | 20.53% | ↗ |
| 21 | 2019 | Jack W. Callicutt, Chief Financial Officer | 285.0K | 233.5K | — | 191.6K | — | 68.1K | 778.1K | 24.62% | ↗ |
| 22 | 2019 | Jack W. Callicutt, Chief Financial Officer | 285.0K | 233.5K | — | 191.6K | — | 68.1K | 778.1K | 24.62% | ↗ |
| 23 | 2018 | Harold H. Shlevin, Ph.D., Chief Executive Officer President | 395.8K | 375.0K | — | 891.1K | — | 68.9K | 1.73M | 51.49% | ↗ |
| 24 | 2018 | Peter G. Traber, M.D. Former Chief Executive Officer President | 270.2K | — | — | 993.5K | — | 44.9K | 1.31M | 75.92% | ↗ |
| 25 | 2018 | Jack W. Callicutt, Chief Financial Officer | 275.3K | 213.8K | — | 715.3K | — | 62.2K | 1.27M | 56.48% | ↗ |
| 26 | 2017 | Peter G. Traber, M.D. Chief Executive Officer President | 512.5K | 299.5K | — | — | — | 65.4K | 877.4K | 0.00% | ↗ |
| 27 | 2017 | Peter G. Traber, M.D. Former Chief Executive Officer President | 512.5K | 299.5K | — | — | — | 65.4K | 877.4K | 0.00% | ↗ |
| 28 | 2017 | Jack W. Callicutt, Chief Financial Officer | 260.0K | 91.2K | — | — | — | 54.8K | 406.0K | 0.00% | ↗ |
| 29 | 2017 | Harold H. Shlevin, Ph.D., Chief Executive Officer President | 260.0K | 91.2K | — | — | — | 54.0K | 405.2K | 0.00% | ↗ |
| 30 | 2017 | Harold H. Shlevin, Ph.D., Chief Operating Officer | 260.0K | 91.2K | — | — | — | 54.0K | 405.2K | 0.00% | ↗ |
| 31 | 2016 | Peter G. Traber, M.D. Chief Executive Officer President | 512.5K | 160.9K | — | 288.1K | — | 60.6K | 1.02M | 28.19% | ↗ |
| 32 | 2016 | Peter G. Traber, M.D. Former Chief Executive Officer President | 512.5K | 160.9K | — | — | — | 60.6K | 1.02M | 0.00% | ↗ |
| 33 | 2016 | Jack W. Callicutt, Chief Financial Officer | 260.0K | 54.2K | — | — | — | 49.1K | 503.9K | 0.00% | ↗ |
| 34 | 2016 | Harold H. Shlevin, Ph.D., Chief Operating Officer | 260.0K | 50.9K | — | 140.6K | — | 48.1K | 499.6K | 28.14% | ↗ |
| 35 | 2016 | Harold H. Shlevin, Ph.D., Chief Executive Officer President | 260.0K | 50.9K | — | — | — | 48.1K | 499.6K | 0.00% | ↗ |
| 36 | 2015 | Peter G. Traber, M.D. Chief Executive Officer President | 500.0K | 210.0K | — | — | — | 55.0K | 1.14M | 0.00% | ↗ |
| 37 | 2015 | James C. Czirr Executive Chairman and Director | 250.0K | 56.9K | — | 169.8K | — | 88.0K | 564.7K | 30.07% | ↗ |
| 38 | 2015 | Harold H. Shlevin, Ph.D., Chief Operating Officer | 250.0K | 66.0K | — | — | — | 40.4K | 462.1K | 0.00% | ↗ |
| 39 | 2015 | Jack W. Callicutt, Chief Financial Officer | 240.0K | 69.1K | — | — | — | 44.4K | 425.9K | 0.00% | ↗ |
| 40 | 2014 | Peter G. Traber, M.D. Chief Executive Officer President | 485.0K | 213.4K | — | — | — | 41.5K | 2.25M | 0.00% | ↗ |
| 41 | 2014 | James C. Czirr Executive Chairman and Director | 240.0K | 84.0K | — | 688.4K | — | 75.9K | 1.09M | 63.25% | ↗ |
| 42 | 2014 | Harold H. Shlevin, Ph.D., Chief Operating Officer | 230.0K | 77.6K | — | — | — | 35.3K | 771.7K | 0.00% | ↗ |
| 43 | 2014 | Jack W. Callicutt, Chief Financial Officer | 175.0K | 38.5K | — | — | — | 38.8K | 545.7K | 0.00% | ↗ |
| 44 | 2013 | Jack W. Callicutt, Chief Financial Officer | 87.5K | 39.8K | — | — | — | 17.1K | 853.9K | 0.00% | ↗ |
| 45 | 2013 | Peter G. Traber, M.D. Chief Executive Officer President | 375.0K | 194.7K | — | — | — | 43.0K | 612.7K | 0.00% | ↗ |
| 46 | 2013 | James C. Czirr Executive Chairman and Director | 240.0K | 120.0K | — | — | — | 77.2K | 437.2K | 0.00% | ↗ |
| 47 | 2013 | Harold H. Shlevin, Ph.D., Chief Operating Officer | 200.0K | 60.0K | — | — | — | 32.5K | 292.4K | 0.00% | ↗ |
| 48 | 2012 | Peter G. Traber, M.D. Chief Executive Officer President | 314.9K | 25.0K | — | 713.3K | — | 36.0K | 1.09M | 65.49% | ↗ |
| 49 | 2012 | Harold H. Shlevin, Ph.D., Chief Operating Officer | 50.0K | 25.0K | — | — | — | 8.9K | 557.3K | 0.00% | ↗ |
| 50 | 2012 | Harold Shlevin, Ph.D., | 50.0K | 25.0K | — | 473.4K | — | 8.9K | 557.3K | 84.94% | ↗ |
| 51 | 2012 | Maureen Foley, Chief Operating Officer | 286.5K | — | — | — | — | 9.3K | 295.8K | 0.00% | ↗ |
| 52 | 2012 | James C. Czirr Executive Chairman and Director | 212.5K | — | — | — | — | 79.7K | 292.2K | 0.00% | ↗ |
| 53 | 2012 | Jack W. Callicutt, Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 54 | 2011 | Peter G. Traber, M.D. Chief Executive Officer President | 147.5K | — | — | 5.56M | — | 22.8K | 5.73M | 97.03% | ↗ |
| 55 | 2011 | Peter G. Traber, M.D. Chief Executive Officer President | 147.5K | — | — | 5.56M | — | 22.8K | 5.73M | 97.03% | ↗ |
| 56 | 2011 | James C. Czirr Executive Chairman and Director | 92.5K | — | — | 3.04M | — | 39.2K | 3.17M | 95.84% | ↗ |
| 57 | 2011 | James C. Czirr Executive Chairman and Director | 92.5K | — | — | 3.04M | — | 39.2K | 3.17M | 95.84% | ↗ |
| 58 | 2011 | Anthony Squeglia, Chief Financial Officer | 147.5K | 60.0K | — | — | — | 30.4K | 237.9K | 0.00% | ↗ |
| 59 | 2011 | Maureen Foley, Chief Operating Officer | 148.1K | 60.0K | — | — | — | 25.0K | 233.1K | 0.00% | ↗ |
| 60 | 2011 | Theodore D. Zucconi, Ph.D., Chief Executive Officer President | 75.8K | — | — | — | — | 4.3K | 80.1K | 0.00% | ↗ |
| 61 | 2010 | Theodore D. Zucconi, Ph.D., Chief Executive Officer President | 120.0K | 80.0K | — | — | — | 28.2K | 228.2K | 0.00% | ↗ |
| 62 | 2010 | Anatole Klyosov, D.Sc. Chief Scientist | 110.0K | — | — | 70.1K | — | 23.5K | 203.7K | 34.44% | ↗ |
| 63 | 2010 | Anthony Squeglia, Chief Financial Officer | 90.0K | — | — | 51.0K | — | 21.6K | 162.6K | 31.37% | ↗ |
| 64 | 2010 | Maureen Foley, Chief Operating Officer | 92.5K | — | — | 51.0K | — | 18.9K | 162.4K | 31.41% | ↗ |
| 65 | 2010 | David Platt, Ph.D., Chief Executive Officer | — | — | — | — | — | 153.6K | 153.6K | 0.00% | ↗ |
| 66 | 2010 | Eliezer Zomer, Ph.D., Executive Vice President of Manufacturing and Product Development | 110.0K | — | — | — | — | 24.5K | 134.5K | 0.00% | ↗ |
| 67 | 2009 | Theodore D. Zucconi, Ph.D., Chief Executive Officer President | 112.0K | 10.0K | — | 905.7K | — | 53.7K | 1.08M | 83.75% | ↗ |
| 68 | 2009 | Eliezer Zomer, Ph.D., Executive Vice President of Manufacturing and Product Development | 104.8K | — | — | 70.7K | — | 28.8K | 204.3K | 34.62% | ↗ |
| 69 | 2009 | David Platt, Ph.D., Chief Executive Officer | 14.0K | — | — | 41.6K | — | 134.9K | 190.5K | 21.84% | ↗ |
| 70 | 2009 | Anatole Klyosov, D.Sc. Chief Scientist | 100.8K | — | — | 30.3K | — | 26.8K | 157.9K | 19.19% | ↗ |
| 71 | 2009 | Anthony Squeglia, Chief Financial Officer | 86.5K | — | — | 50.5K | — | 20.7K | 157.7K | 32.03% | ↗ |
| 72 | 2009 | Maureen Foley, Chief Operating Officer | 88.8K | — | — | 30.3K | — | 17.6K | 136.7K | 22.18% | ↗ |
| 73 | 2008 | David Platt, Ph.D., Chief Executive Officer | 141.0K | — | — | 64.3K | — | 40.2K | 245.5K | 26.18% | ↗ |
| 74 | 2008 | Theodore D. Zucconi, Ph.D., Chief Executive Officer President | 137.2K | — | — | 48.2K | — | 39.5K | 224.9K | 21.44% | ↗ |
| 75 | 2008 | Eliezer Zomer, Ph.D., Executive Vice President of Manufacturing and Product Development | 124.3K | — | — | 48.2K | — | 29.3K | 201.8K | 23.89% | ↗ |
| 76 | 2008 | Theodore Zucconi, Ph.D., President | 137.2K | — | — | 48.2K | — | 39.5K | 176.7K | 27.29% | ↗ |
| 77 | 2007 | David Platt, Ph.D., Chief Executive Officer | 195.0K | — | — | 86.3K | — | 49.9K | 331.1K | 26.05% | ↗ |
| 78 | 2007 | Eliezer Zomer, Ph.D., Executive Vice President of Manufacturing and Product Development | 165.0K | — | — | 85.7K | — | 26.9K | 277.5K | 30.86% | ↗ |
| 79 | 2007 | Maureen Foley, Chief Operating Officer | 138.8K | — | — | 85.7K | — | 18.6K | 243.0K | 35.24% | ↗ |
| 80 | 2007 | Theodore Zucconi, Ph.D., President | 55.4K | — | — | — | — | 16.3K | 224.9K | 0.00% | ↗ |
| 81 | 2006 | David Platt, Ph.D., Chief Executive Officer | 260.0K | — | — | 45.8K | — | 50.9K | 356.7K | 12.85% | ↗ |
| 82 | 2006 | Eliezer Zomer, Ph.D., Executive Vice President of Manufacturing and Product Development | 220.0K | — | — | 59.5K | — | 29.2K | 308.7K | 19.27% | ↗ |
| 83 | 2006 | Maureen Foley, Chief Operating Officer | 185.0K | — | — | 59.5K | — | 22.4K | 266.9K | 22.29% | ↗ |
| 84 | 2005 | Carl Lueders, Chief Financial Officer | 179.7K | 31.5K | — | — | — | — | 211.2K | 0.00% | ↗ |
| 85 | 2004 | David Platt, President and Chief Executive Officer | 222.9K | 100.0K | — | — | — | — | 322.9K | 0.00% | ↗ |
| 86 | 2004 | Maureen Foley, Chief Operating Officer | 153.4K | — | — | — | — | — | 153.4K | 0.00% | ↗ |
| 87 | 2003 | David Platt, President and Chief Executive Officer | 180.0K | — | — | — | — | — | 180.0K | 0.00% | ↗ |
| 88 | 2003 | James Czirr, former Executive Vice President, Business Development | 122.5K | — | — | — | — | — | 122.5K | 0.00% | ↗ |
| 89 | 2003 | Maureen Foley, Chief Operating Officer | 120.0K | — | — | — | — | — | 120.0K | 0.00% | ↗ |
| 90 | 2003 | David Christopher, former Chief Financial Officer | 100.5K | — | — | — | — | — | 100.5K | 0.00% | ↗ |
| 91 | 2002 | David Platt, President and Chief Executive Officer | 157.5K | 35.0K | — | — | — | — | 192.5K | 0.00% | ↗ |
| 92 | 2002 | Maureen Foley, Chief Operating Officer | 83.8K | — | — | — | — | — | 83.8K | 0.00% | ↗ |
| 93 | 2002 | James Czirr, former Executive Vice President, Business Development | 70.0K | — | — | — | — | — | 70.0K | 0.00% | ↗ |
| 94 | 2002 | James Czirr, Executive Vice President, Business Development | 1.00 | — | — | — | — | — | 1.00 | 0.00% | ↗ |
| 95 | 2002 | David Christopher, former Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 96 | 2001 | David Platt, President and Chief Executive Officer | 166.7K | — | — | — | — | — | 166.7K | 0.00% | ↗ |
| 97 | 2001 | James Czirr, Executive Vice President, Business Development | 120.0K | — | — | — | — | — | 120.0K | 0.00% | ↗ |
| 98 | 2001 | Maureen Foley, Chief Operating Officer | 50.0K | — | — | — | — | — | 50.0K | 0.00% | ↗ |
| 99 | 2001 | James Czirr, former Executive Vice President, Business Development | — | — | — | — | — | — | — | — | ↗ |
| 100 | 2001 | David Christopher, former Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 101 | 2000 | David Platt, President and Chief Executive Officer | 25.0K | — | — | — | — | — | 25.0K | 0.00% | ↗ |
| 102 | 2000 | James Czirr, Executive Vice President, Business Development | 2.00 | — | — | — | — | — | 2.00 | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Joel Lewis | President & CEO | 992.0K | male |
| Khurram Jamil | Chief Medical Officer | 921.6K | male |
| Jack W. Callicutt | Chief Financial Officer, Treasurer & Corporate Secretary | 676.0K | male |
| Beth Knowles | Executive Assistant & Officer Manager | — | female |
| Jim Wilkins | Head of CMC & Pharmaceutical Development | — | male |
| Robert Tritt | General Counsel | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GALT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
